Patent 8974812 was granted and assigned to Allergan, Inc. on March, 2015 by the United States Patent and Trademark Office.
Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.